Chiome Bioscience (TSE:4583) GF Value Rank: 2 (As of Aug. 07, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
42 GF Score
Price 円70.00
GF Value 円105.64
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience GF Value Rank?

Chiome Bioscience TSE:4583 42 GF Value Rank is 2 as of Aug. 07, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates TSE:4583 with a GF Score™ of 42/100 and a GF Value™ of 円105.64 (Possible Value Trap). The stock has 2 warning signs investors should review.

Chiome Bioscience has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Chiome Bioscience GF Value Rank Related Terms


TSE:4583 vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, Chiome Bioscience's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's GF Value Rank falls into.


TSE:4583
42GF Score
Chiome Bioscience Inc TSE:4583
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Chiome Bioscience (TSE:4583) has a GF Value Rank of 2 as of Aug. 07, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Chiome Bioscience and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Chiome Bioscience's GF Value Rank has ranged from 1.00 to 10.00.
Is Chiome Bioscience's GF Value Rank too high?
Chiome Bioscience's current GF Value Rank of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Chiome Bioscience has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's GF Value Rank compare to VRTX and REGN?
Chiome Bioscience's GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Chiome Bioscience's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current GF Value Rank is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円105.64, compared to a current price of 円70.00 — trading 33.7% below its estimated fair value. The current GF Value Rank is 2, which is 50% below median its 10-year median of 4.00. Chiome Bioscience's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current GF Value Rank is 2 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円70.00 is trading 33.7% below its estimated GF Value™ of 円105.64. GuruFocus considers Chiome Bioscience to be Possible Value Trap.

Key valuation signals for TSE:4583:

  • GF Value Rank: 2 (50% below median its 10-year median of 4.00)
  • GF Value™: 円105.64 vs. price of 円70.00 (33.7% below fair value)
  • GF Score™: 42/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
42GF Score

Get the complete analysis for TSE:4583

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円70.00
Price
円105.64
GF Value